Get The Latest News And Stock Price Of ADAP Adaptimmune With Nasdaq ADAP

By | August 27, 2020

Adaptimmune aims in providing better services to cancer patients through immunotherapy. The lives of cancer patients need frequent treatment to live happily. The outcome of patients is improved when they receive proper treatment and medication. Adaptimmune creates helpful resources available for both patients and families. The company develops T-cell therapies that destroy the cancerous cells. This also helps the immune system to target and detect cancer cells. Adaptimmune services targets in improving the natural immune system of patients’ bodies to defend the cancer cells and bind the T-cells optimization.

The receptors of T-cell recognize the cancer cells and clears them from the body. There is a complete procedure of how the company functions from collecting apheresis to cryopreservation. Adapatimuumne is consistently investing in its manufacturing process to make its service efficient and scalable. With NASDAQ: ADAP at, you can get the latest updates about the happenings of Adaptimmune. For investors, it is important to know the stock price of a company.

Stock details of Adaptimmune

Following is the detail of one day latest stock info


Last- 8.01


Previous close-7.86




Percentage of change-1.91%

After hours




Percentage of change-1.12%

Share info

Year high-13.40

Shares out-154.61m

PB ratio-3.304

Year low-0.71

Market cap-1.24b


EPS – -1.32

With interactive customised stock charts, one can check the earnings, splits and even dividends easily. Even pre and post-market prices are also visible easily from the charts.

Historical data is another way of viewing the stocks easily with advanced filters. Filters like highs, lows, VWAPS, opens, volume change and more can be applied while seeking data. One can also view the firms and analysts using analyst coverage of the company.

Adaptimmune technology

The primary aim of Adaptimmune is to revolutionize cancer therapy treatment throughout the globe. The company aims to achieve this by developing TCR T-cell therapies. TCR cell therapy is better than other immune therapies and has a lot of advantages. These cells recognize peptide fragments from proteins within the cell. Hence, it can target many proteins which also means targeting many cancers.

The company aims to target solid tumors with Tcell therapies. Even cancer that has low survival chances can also be treated to an extent with Tcell therapy. You can find the best broker for day trading.

Read in details about the company services and features at its official sites. If you are an investor and want to know more about the stock trend of the company browse NASDAQ: ADAP.

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.